Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05125055 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 22, 2023 (before its estimated September 30, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Sep 30, 2023 to Sep 30, 2024
    • Study completion date: Dec 30, 2025 to Dec 30, 2026
    v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel /Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patients with locally advanced resectable oral squamous cell carcinoma (OSCC), and to determine the safety of neoadjuvant TTP. In order to explore a better protocol of neoadjuvant therapy to improve the efficacy in patients with locally advanced OSCC.
Trial Details
NCT Number NCT05125055
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions
(from sponsor)		 Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
Related terms Squamous Cell Carcinoma of Head and Neck
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov